Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-124

Hi Doc Mcstuffins
Have you published any observational pieces in Medical Publications?
If so, then you should understand this process.
This is an observational piece. It is not a clinical trial. There are no comparative stats involved; no RCT.
This is communication with peers. Information sharing. Nothing more, nothing less. People with medical qualifications reading this article would understand this.

I am starting to question your qualifications (something I have not done before) because of the arguments you are presenting with regard to this article. If you were a medical doctor (MBBS) you would have submitted a number of these articles for publication during your intern and registrar years and would understand the process. Have you an MBBS qualification? Could you please answer this question?

It was not market sensitive because it is an observational piece. It is communicating to peers. It will not be read by FDA or used in FDA submissions.
It seems MSB is damned if they do, damned if they don't.
You want communication of what they are doing? Here it is. Now they are being accused of 'pumping'?